Metabolism-Clinical and Experimental

Papers
(The H4-Index of Metabolism-Clinical and Experimental is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on410
Obesity in patients with COVID-19: a systematic review and meta-analysis340
Insulin resistance, cardiovascular stiffening and cardiovascular disease321
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses308
Epidemiology of sarcopenia: Prevalence, risk factors, and consequences201
MAFLD and risk of CKD200
Role of the gut microbiota in type 2 diabetes and related diseases187
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease150
The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis143
Metformin: Is it a drug for all reasons and diseases?134
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk128
Insulin resistance and insulin sensitizing agents120
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes117
Insulin: The master regulator of glucose metabolism117
Visceral fat is associated to the severity of COVID-19105
The serum metabolome of COVID-19 patients is distinctive and predictive102
Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: A dose-response meta-analysis99
Heart failure in diabetes98
Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy91
FUNDC1 insufficiency sensitizes high fat diet intake-induced cardiac remodeling and contractile anomaly through ACSL4-mediated ferroptosis88
The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis78
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression77
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?73
Mediterranean diet as a nutritional approach for COVID-1969
Diabetes and COVID-19: The past, the present, and the future66
Factors affecting weight loss variability in obesity65
Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies64
Letter to the Editor: Vitamin D deficiency in COVID-19: Mixing up cause and consequence64
Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data63
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes63
Impact of body composition on COVID-19 susceptibility and severity: A two-sample multivariable Mendelian randomization study62
Mitochondrial quality control mechanisms as molecular targets in diabetic heart62
The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000–201961
Mitochondrial dysfunction in diabetic tubulopathy61
Transition of acute kidney injury to chronic kidney disease: role of metabolic reprogramming59
A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage58
Pharmacotherapy of type 2 diabetes: An update and future directions57
FOS/GOS attenuates high-fat diet induced bone loss via reversing microbiota dysbiosis, high intestinal permeability and systemic inflammation in mice57
UCP1-dependent and UCP1-independent metabolic changes induced by acute cold exposure in brown adipose tissue of mice56
Myocardial ketone body utilization in patients with heart failure: The impact of oral ketone ester55
Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy54
Functions of amyloid precursor protein in metabolic diseases54
Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway54
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis53
METTL3 is required for maintaining β-cell function51
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease50
Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus50
Sarcopenia, osteoporosis and frailty50
Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts49
Metabolic dysfunction–associated fatty liver disease and the risk of 24 specific cancers49
0.050167083740234